Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis

被引:5
作者
Song, Qi-Bin [1 ]
Wang, Qi [1 ]
Hu, Wei-Guo [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430060, Hubei Province, Peoples R China
关键词
Colorectal neoplasm; Kirsten rat sarcoma viral oncogene homolog; Cetuximab; Panitumumab; Meta-analysis; PHASE-III TRIAL; 1ST-LINE TREATMENT; PLUS OXALIPLATIN; FINAL REPORT; CETUXIMAB; FLUOROURACIL; LEUCOVORIN; CHEMOTHERAPY; PANITUMUMAB; THERAPY;
D O I
10.3748/wjg.v21.i14.4365
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the correlation between Kirsten rat sarcoma viral oncogene homolog (KRAS) status and the therapeutic effects of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in metastatic colorectal cancer (mCRC). METHODS: Randomized controlled trials (RCTs) were identified and the association between KRAS mutation and clinical outcome in mCRC patients treated with anti-EGFR MoAbs was investigated. Ten RCTs were included in this meta-analysis. Progression-free survival and overall survival were used to assess the strength of the relationship between KRAS mutation and clinical outcome. RESULTS: In first-line treatment, survival benefit was confined to patients with wild-type KRAS. Chemotherapy regimens and angiogenesis inhibitor treatment influenced the results of the analysis. Wildtype KRAS mCRC patients did not seem to benefit from oxaliplatin-based chemotherapy (PFS: HR = 0.88, 95% CI: 0.70-1.10; OS: HR = 0.93, 95% CI: 0.82-1.04). Clinical benefit in mCRC patients was limited to therapeutic regimens which included anti-EGFR MoAbs and fluorouracil-based therapy (PFS: HR = 0.77, 95% CI: 0.69-0.86; OS: HR = 0.85, 95% CI: 0.75-0.95). When anti-EGFR MoAbs were used as second-or further-line treatment, clinical benefit was still confined to patients with wild-type KRAS. CONCLUSION: KRAS status is a potential predictive marker of clinical benefit due to anti-EGFR MoAb therapy in mCRC patients.
引用
收藏
页码:4365 / 4372
页数:8
相关论文
共 26 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers [J].
Barault, Ludovic ;
Veyrie, Nicolas ;
Jooste, Valerie ;
Lecorre, Delphine ;
Chapusot, Caroline ;
Ferraz, Jean-Marc ;
Lievre, Astrid ;
Cortet, Marion ;
Bouvier, Anne-Marie ;
Rat, Patrick ;
Roignot, Patrick ;
Faivre, Jean ;
Laurent-Puig, Pierre ;
Piard, Francoise .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (10) :2255-2259
[3]   Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
de Braud, F. ;
Schuch, G. ;
Zubel, A. ;
Celik, I. ;
Schlichting, M. ;
Koralewski, P. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546
[4]   Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial [J].
Diaz-Rubio, Eduardo ;
Tabernero, Jose ;
Gomez-Espana, Auxiliadora ;
Massuti, Bartomeu ;
Sastre, Javier ;
Chaves, Manuel ;
Abad, Alberto ;
Carrato, Alfredo ;
Queralt, Bernardo ;
Reina, Juan Jose ;
Maurel, Joan ;
Gonzalez-Flores, Encarnacion ;
Aparicio, Jorge ;
Rivera, Fernando ;
Losa, Ferran ;
Aranda, Enrique .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4224-4230
[5]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[6]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[7]   Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first- line treatment of metastatic colorectal cancer: Updated results from the BICC-C study [J].
Fuchs, Charles S. ;
Marshall, John ;
Barrueco, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :689-690
[8]   Validation of Companion Diagnostic for Detection of Mutations in Codons 12 and 13 of the KRAS Gene in Patients with Metastatic Colorectal Cancer Analysis of the NCIC CTG CO.17 Trial [J].
Harbison, Christopher T. ;
Horak, Christine E. ;
Ledeine, Jean-Marie ;
Mukhopadhyay, Pralay ;
Malone, Daniel P. ;
O'Callaghan, Chris ;
Jonker, Derek J. ;
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Gustafson, Nancy ;
Trifan, Ovidiu C. ;
Chang, Shao-Chun ;
Ravetto, Paul ;
Green, George A. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (06) :820-827
[9]   A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer [J].
Hecht, J. Randolph ;
Mitchell, Edith ;
Chidiac, Tarek ;
Scroggin, Carroll ;
Hagenstad, Christopher ;
Spigel, David ;
Marshall, John ;
Cohn, Allen ;
McCollum, David ;
Stella, Philip ;
Deeter, Robert ;
Shahin, Seta ;
Amado, Rafael G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :672-680
[10]   Measuring inconsistency in meta-analyses [J].
Higgins, JPT ;
Thompson, SG ;
Deeks, JJ ;
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560